INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

Core Viewpoint - Atara Biotherapeutics is under investigation for potential securities fraud and unlawful business practices following significant stock price declines due to regulatory issues with its drug application and clinical trials [1][2][3]. Group 1: Regulatory Issues - On January 16, 2025, Atara received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for EBVALLO, leading to a stock price drop of $6.59 per share, or 50.08$6.57 per share [2]. - On January 21, 2025, the FDA placed a clinical hold on Atara's active Investigational New Drug (IND) applications due to compliance issues identified during the pre-license inspection, resulting in a further stock price decline of $0.52 per share, or 7.91$6.05 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Atara investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].